MarketPulse

Phase 1 data

2 articles
The Motley FoolThe Motley Fool··Lee Samaha

Ovid Therapeutics Surges 18% on Positive Phase 1 Data for OV329 Epilepsy Drug

Ovid Therapeutics surges 18% after Phase 1 data shows OV329 epilepsy drug eliminated safety concerns. Company secures $60M to fund Phase 2 trials.
OVIDbiotechprivate placement
The Motley FoolThe Motley Fool··Jonathan Ponciano

First Turn Management Establishes $35M Stake in Clinical-Stage Biotech Terns

First Turn Management invests $35M in clinical-stage biotech Terns Pharmaceuticals, acquiring 4.03% stake. Stock surged 826% year-over-year on cancer drug trial progress.
TERNdrug developmentstock surge